New drugs both reduce bone loss and increase bone mass
|
Categories |
Bone, osteoporosis, fatty acids/lipidomics |
|
Development Stage |
Proof of concept – small animals |
|
Patent Status |
PCT published: WO 2009/125409 |
Highlights
-
Many medical conditions, such as osteoporosis and skeletal injuries, are associated with loss of bone tissue.
-
Bone mass is determined by a continuous remodeling process in which the mineralized matrix is removed by osteoclasts and subsequently replaced with newly formed bone tissue produced by osteoblasts.
-
Fatty acid amides of amino acids are produced endogenously in bone and have been found to play a significant role in this process.
-
Of these fatty acid amides, N-oleoyl-L-serine (OS) had the highest stimulatory activity in osteoblast proliferation assays. It also inhibits osteoclast formation and stimulates osteoclast apoptosis.
-
In intact and osteoporotoc mice, OS effectively increases bone mass by enhancing bone formation and markedly restraining bone resorption.
Our Innovation
Fatty acid amides of amino acids, such as N-oleoyl-L-serine (OS), as the basis for drugs for the simulation of bone growth and repair and the prevention of bone loss. OS is a novel lipid regulator of bone remodeling and represents a new lead to antiosteoporotic drug discovery.
Key Features
-
Reduces bone loss as well as increasing bone mass
-
Advantageous to currently available therapies, which are essentially either pro-formative or anti-resorptive
-
Naturally occurring compounds
-
Low cost of synthetic production
Development Milestones
Seeking licensing cooperation and funding for continuing research
The Opportunity
Applications for osteoporosis, healing of fractures and other skeletal injuries as well as orthopaedic and dental implantation.1586128900.png)